{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-015686","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.691485+00:00","generated_at":"2026-06-02T06:29:52.138099+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eton Pharma Q1 revenue $8.0M (+50% YoY); acquires PKU GOLIKE; submits NDA for ET-400","bullets":["Q1 2024 revenue $8.0M, up 50% YoY; net loss narrowed to $0.8M from $2.7M.","Acquired U.S. rights to PKU GOLIKE for PKU; market ~$100M; targeting $10M annual sales.","Submitted NDA for ET-400 (hydrocortisone oral solution); potential approval Q1 2025; peak sales >$50M combined.","Launched Nitisinone in Feb 2024; $50M market; cross-selling opportunities with Carglumic Acid and PKU GOLIKE."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-015686","json":"https://secwatch.observer/filing/0001437749-24-015686.json","markdown":"https://secwatch.observer/filing/0001437749-24-015686.md","text":"https://secwatch.observer/filing/0001437749-24-015686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/0001437749-24-015686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/eton20240426_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:29:52.138099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a7c4364052482b0000d3fc188e588bd3befbd69","claim":"Eton Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $8.0 million, net income Net loss for the first quarter of 2024 was $0.8 million, EPS $0.03 per basic and diluted share.","evidence_excerpt":"Net revenues for the first quarter of 2024 were $8.0 million compared with $5.3 million in the prior year period, an increase of 50%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/0001437749-24-015686-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$8.0 million"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $0.8 million"},{"label":"EPS","value":"$0.03 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}